Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

The Impact of Biologics on the Treatment of CRSwNP: Targeting Type 2 Inflammation

Premiere Date: Friday, April 22, 2022

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, April 22, 2023
Note: Credit Is No Longer Available

Faculty

Joseph K. Han, MD, FARS, FAAAAI (Moderator) Professor Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery Chief, Division of Allergy Eastern Virginia Medical School Norfolk, VA ARS, Immediate Past President AAAAI, RROAC, Chair

Stella Lee, MD  Section Chief, Rhinology Division of Otolaryngology-Head & Neck Surgery Brigham and Women's Hospital Harvard Medical School Boston, MA

Statement of Need

The pathophysiology of chronic rhinosinusitis with nasal polyposis (CRSwNP) is complex, including the pathways of type 2 inflammation. As understanding of the underlying pathophysiology of CRSwNP expands, so does the potential list of targeted biologic therapies that may produce superior outcomes and safety compared to standard therapy. Determining how these agents are best utilized in CRSwNP requires additional research, and until then, many questions remain. Currently, there remains a lack of consensus on the correct timing of these medications, and clinicians require education on contemporary research regarding the use of biologics in CRSwNP.

Please join Dr. Han and Dr. Lee in part 3 of a CMEO Snack series on CRSwNP, as they discuss the pathophysiology of CRSwNP and safety and efficacy data for biologics targeting type 2 inflammation and individualizing treatment.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Apply efficacy and safety data to treatment decisions for patients with CRSwNP.

Financial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

UEMS-EACCME:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Han reports the following financial relationships:

Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme

Dr. Lee reports the following financial relationships:

Consultant and Research Support: AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Sanofi Regeneron

The following peer reviewer and CME Outfitters staff have no financial relationships:

Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)

Janan Sarwar, PharmD (planning committee)

Evan Luberger (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).